Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
This combination regimen includes **epcoritamab** (a subcutaneous bispecific CD3xCD20 antibody), **polatuzumab vedotin** (an antibody-drug conjugate targeting CD79b), **rituximab** (a CD20 monoclonal antibody), **cyclophosphamide** (an alkylating agent), **doxorubicin** (an anthracycline cytotoxic agent), and **prednisone** (a corticosteroid). This approach is under clinical investigation as first-line treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL). Epcoritamab enhances T cell-mediated cytotoxicity by binding CD3 on T cells and CD20 on B cells; polatuzumab vedotin delivers a microtubule-disrupting cytotoxin to CD79b+ B cells; rituximab mediates B cell lysis through anti-CD20 targeting; cyclophosphamide and doxorubicin introduce cytotoxic damage to cancer cells; prednisone suppresses inflammation and immune responses. The combination aims to further improve response rates and depth of remission over conventional immunochemotherapy.
- Other names
- pola-R-CHP + epcoritamab
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)B-cell antigen receptor complex-associated protein beta chainTOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on epcoritamab + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.